Selective β3 adrenergic agonists

A pharmaceutical formulation comprising a compound represented by the following structural Formula (I):

• wherein:
• X1 is —OCH2—, —SCH2—, or a bond;
• R1 is a heterocycle of the formula:
• R2 and R3 are independently hydrogen, C1-C4 alkyl, or aryl;
• R4 is:
• 1) an optionally substituted heterocycle selected from the group consisting of pyrazolyl, pyrazolinyl, imidazolyl, isoxazolyl, triazolyl, tetrazolyl, oxazolyl, 1,3-dioxolonyl, thiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, piperazinyl, morpholinyl, pyrazinyl, pyrrolidinyl, piperidinyl, oxazolidonyl, oxazolidinedionyl and imidazolidinonyl;
• or
• 2) a moiety selected from the group consisting of:
• X2 is a bond, or a 1 to 5 carbon straight or branched alkylene;
• R5 is hydrogen or C1-C4 alkyl;
• R6 is hydrogen or C1-C4 alkyl;
• or R5 and R6 combine with the carbon to which each is attached to form a C3-C6 cycloalkyl;
• or R6 combines with X2 and the carbon to which each is attached to form a C3-C8 cycloalkyl;
• R7 is hydrogen, hydroxy, cyano, oxo, COnR2, —CONHR2, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 optionally substituted alkyl, (CH2)n aryl, (CH2)nheterocycle, (CH2)n optionally substituted aryl, or (CH2)n optionally substituted heterocycle;
• R8 is independently hydrogen, halo, or C1-C4 alkyl;
• R9 is halo, CN, OR10, C1-C4 alkyl, C1-C4 haloalkyl, CO2R2, CONR11R12, CONH(C1-C4 alkyl or C1-C4 alkoxy), SR2, CSNHR2, CSNR11R12, SO2R2, SOR2, NR11R12, optionally substituted aryl, optionally substituted heterocycle, or C2-C4 alkenyl substituted with CN, CO2R2, or CONR11R12;
• R10 is C1-C4 alkyl, C1-C4 haloalkyl, (CH2)nC3-C8 cycloalkyl, (CH2)naryl, (CR2)nheterocycle, (CH2)nC3-C8 optionally substituted cycloalkyl, (CH2)n optionally substituted aryl, or (CH2)n optionally substituted heterocycle;
• R11 and R12 are independently hydrogen, C1-C4 alkyl, aryl, (CH2)naryl, or combine with the nitrogen to which each is bound to form morpholinyl, piperidinyl, pyrrolidinyl, or piperazinyl;
• R13 is hydrogen, halo, aryl, or C1-C4 alkyl;
• m is 0 or 1;
• n is 0, 1, 2, or 3;
• provided that when R4 is
• then R9 is not (C1-C4 alkyl, C1-C4 haloalkyl;
• or a pharmaceutically acceptable salt thereof;
• and one or more pharmaceutically acceptable carriers, diluents or excipients.